There are benefits to starting from zero.
In 2012, our founding team learned cellular reference material, used as a control for drug development (Dv) and diagnostics (Dx), is sourced and generated from human and animal donors. This seemed crazy to us. To name just a few issues, the existing products were prone to supply chain issues, biological noise, and fundamentally high cost (precluding access to this material for developing nations).
As we dug in more to this problem, the challenge was clear: we needed to make a low-cost synthetic cell (biochemically and optically complex) that retained the benefits of synthetic materials (cheap/scalable production):
Our company's solution to such a fundamental issue is FlowCytes.